Drug intelligence / Profile preview

EX109

Development stage: Preclinical
Lead developer: Guangzhou Excelmab
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EX109 is a preclinical-stage bispecific T-cell engager (BiTE) developed by Guangzhou Excelmab for the treatment of gastric cancer. The therapeutic is designed to simultaneously target Mucin 17 (MUC17), a cell surface glycoprotein frequently overexpressed in gastric malignancies, and the CD3 subunit of the T-cell receptor complex. By bridging these two targets, EX109 facilitates the formation of an immunological synapse, leading to the localized activation of T cells and subsequent cytotoxic elimination of MUC17-positive tumor cells.

Targets

CD3 (T-cell surface glycoprotein CD3)MUC17 (Mucin 17, cell surface associated)

Beyond the preview

Go deeper on EX109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EX109.

Explore the full profile